A Vaccine to Attack Ovarian Cancer

Why is research on ovarian cancer so critical? Ovarian cancer is the fifth most common cancer among women. Ovarian cancer research efforts create and define new protocols for early detection, prevention and advanced therapy application.

Despite advances in chemotherapy over the years, the death rate from ovarian cancer has not changed significantly in more than four decades. There are few, if any, early symptoms of the disease, which makes it difficult to detect ovarian cancer in a routine physician’s exam.

Currently, there is no consistently reliable, accurate screening test to detect ovarian cancer. However, researchers at Penn’s Ovarian Cancer Research Center and the Abramson Cancer Center of the University of Pennsylvania have developed a method to use a patient’s own tumor tissue to create an immunotherapy vaccine to attack ovarian cancer. In fact, Penn research efforts have resulted in a clinical trial that is currently testing the effectiveness of this immunotherapeutic ovarian cancer vaccine.

Read More        About Our Team

Diabetes Control Through Education and Lifestyle

Type 2 diabetes poses a major public health threat in the U.S. It is already the costliest chronic illness in the country and its prevalence is increasing rapidly. Currently, nearly 21 million Americans have type 2 diabetes and 53 million Americans have pre-diabetes, which puts them at significant risk for developing the disease.

During the past 20 years, the average age of diagnosis has steadily dropped from 52 to 46. Today, one in 15 Americans is diabetic. Without major lifestyle changes, many Americans are facing a future overwhelmed by diabetes-related health complications and costs.

Read More        Services and Programs

Transforming Cardiovascular Medicine Through Research

Over the past decade, cardiovascular research and clinical care at the University of Pennsylvania has grown tremendously with many nationally and internationally recognized research and clinical programs. The Penn Cardiovascular Institute (CVI) was established in 2005 to build bridges between scientists and clinicians. This collaborative spirit has facilitated the development of novel treatments and therapies, which patients at Penn have been among the first in the world to benefit from.

Our researchers and clinicians continue to discover new breakthroughs that lead to life-saving procedures, devices and medications that will positively impact the care of individuals with cardiovascular disease.

Read More

subscriber information	click here to UNSUBSCRIBE